Key result
Antiarrhythmic drugs may directly or indirectly interact with implantable cardioverter defibrillator function, particularly in patients with multiple comorbidities.
This review highlights the importance of recognizing potential interactions between antiarrhythmic drugs and ICD function in clinical practice.
Answers are grounded in this paper and cite their sources.
Supports monitoring for antiarrhythmic-ICD interactions in multimorbid patients; leaves open prospective validation of specific risks.
Antiarrhythmic drugs are commonly used synergistically with implantable cardioverter defibrillators in the management of ventricular and supraventricular arrhythmias. However, these drugs may directly or indirectly interact with device function. In addition, expanding indications for implantable cardioverter defibrillators, particularly in patients with multiple comorbidities, further increases the potential for drug-device interactions. These potential drug-device interactions are summarized in this article.
No takes yet. Share an insight, caveat, or question.
Beadle et al. (2010) conducted a review in Ventricular and supraventricular arrhythmias in patients with implantable cardioverter defibrillators. Antiarrhythmic drugs was evaluated. Antiarrhythmic drugs may directly or indirectly interact with implantable cardioverter defibrillator function, particularly in patients with multiple comorbidities.
Synapse has enriched 10 related papers. Consider them for comparative context: